Wiener klinische Wochenschrift Education

, Volume 3, Issue 1, pp 59–77

Chronische Myeloproliferative Erkrankungen (CMPE)

  • Ernst Rechberger
  • Gerald Webersinke
  • Andreas L. Petzer
Article
  • 88 Downloads

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Dameshek W (1951) Some speculations on the myeloproliferative syndromes. Blood 6: 372–375PubMedGoogle Scholar
  2. Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132: 1497–1501Google Scholar
  3. Rowley JD (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining (letter). Nature 243: 290–293PubMedCrossRefGoogle Scholar
  4. Fialkow PJ, Jacobson RJ, Papayannopoulou T (1997) Chronic myelocytic leukemia: clonal origin in a stem cell common to the granulocyte, erythrocyte, platelet and monocyte/macrophage. Am J Med 63: 125–130CrossRefGoogle Scholar
  5. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, ber, on chromosome 22. Cell 36: 93–99PubMedCrossRefGoogle Scholar
  6. MacKinney AA Jr, Clark SS, Borcherding W, Fizzotti M, Hong R (1993) Simultaneous demonstration of the Philadelphia chromosome in T, B, and myeloid cells. Am J Hematol 44: 48–52PubMedCrossRefGoogle Scholar
  7. Eibl B, Ebner S, Duba C, Böck G, Romani N, Erdel M, Gächter A, Niederwiser D, Schuler G (1997) Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response. Genes Chromosomes Cancer 20: 215–223PubMedCrossRefGoogle Scholar
  8. Hehlmann H, Heimpel J, Hasford J, Kolb HJ, Pralle H, Hossfeld DK, Queißer W, Löffler H, Hochhaus A, Heinze B, Georgii A, CR Bartram, Grießhammer M, Bergmann L, Essers U, Falge C, Queißer U, Meyer P, Schmitz N, Eimermacher H, Walther F, Fett W, Kleeber UR, KäbischA, Nerl C, Zimmermann R, Meuret G, Tichelli A, Kanz L, Tigges F, Schmid L, BrockhausW, Tobler A, Reiter A, Perker M, Emmerich B, Verpoort K, Zankovich R, Wussow P, Prümmer O, Thiele J, Buhr T, Carbonell F, Ansari H (1994) Randomized Comparison of Interferon-α With Busulfan and Hydroxyurea in Chronic Myelogenous Leukemia. Blood 84: 4064–4077PubMedGoogle Scholar
  9. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ (1988) Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61: 1441–1446PubMedCrossRefGoogle Scholar
  10. Sokal JE, Baccarani M, Russo D, Tura S (1988) Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 25: 49–61PubMedGoogle Scholar
  11. Vardiman JW (2003) The new World Health Organization classification of myeloid neoplasms. MD. Clin Adv Hematol Oncol 1: 18–21PubMedGoogle Scholar
  12. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R (2006) Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 108: 1809–1820PubMedCrossRefGoogle Scholar
  13. Hochhaus A, Druker BJ, Larson RA, O'Brien SG, Gathmann I, Guilhot Francois (2007) IRIS 6-Year Follow-Up: Sustained Survival and Declining Annual Rate of Transformation in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) treated with Imatinib. Blood 110: Abstract 25Google Scholar
  14. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, Tso CY, Braun TJ, Clarkson BD, Cervantes F (1984) Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63: 789–799PubMedGoogle Scholar
  15. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans JC, Alimena G, Steegmann JL, Ansari H (1998) A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90: 850–858PubMedCrossRefGoogle Scholar
  16. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, Reiffers J, Cornelissen JJ, Hughes T, Agis H, Fischer T, Verhoef G, Shepherd J, Saglio G, Gratwohl A, Nielsen JL, Radich JP, Somsson B, Taylor K, Baccarani M, So C, Letvak L, Larson RA; IRIS Investigators (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355: 2408–2417PubMedCrossRefGoogle Scholar
  17. Kantarjian HM, Smith TL, O'Brien S, Beran M, Pierce S, Talpaz M, The Leukemia Service (1995) Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy. Ann Intern Med 122: 254–261PubMedGoogle Scholar
  18. Guilhot F, Larson R, O'Brian S, Gathmann I, Druker B (2007) Time to Complete Cytogenetic Response (CCyR) Does not affect long-term outcomes for patients on Imatinib therapy. Blood 110: Abstract 27Google Scholar
  19. Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, Cummings CC, Chu S, Bhatia R, Forman SJ, Negrin RS, Appelbaum FR, Radich JP (2007) The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 109: 1782–1789PubMedCrossRefGoogle Scholar
  20. Grathwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A (1998) Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation for chronic myelogenous leukaemia. Lancet 352: 1087–1092CrossRefGoogle Scholar
  21. Branford S (2007) Chronic myeloid leukemia: molecular monitoring in clinical practice. ASH Education Program Book 376–383Google Scholar
  22. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, Vassiliou GS, Bench AJ, Boyd EM, Curtin N, Scott MA, Erber WN, Green AR (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365: 1054–1061PubMedGoogle Scholar
  23. James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, Garçon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434: 1144–1148PubMedCrossRefGoogle Scholar
  24. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, Boggon TJ, Wlodarska I, Clark JJ, Moore S, Adelsperger J, Koo S, Lee JC, Gabriel S, Mercher T, D'Andrea A, Fröhling S, Döhner K, Marynen P, Vandenberghe P, Mesa RA, Tefferi A, Griffin JD, Eck MJ, Sellers WR, Meyerson M, Golub TR, Lee SJ, Gilliland DG (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387–397PubMedCrossRefGoogle Scholar
  25. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352: 1779–1790PubMedCrossRefGoogle Scholar
  26. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L, Score J, Seear R, Chase AJ, Grand FH, White H, Zoi C, Loukopoulos D, Terpos E, Vervessou EC, Schultheis B, Emig M, Ernst T, Lengfelder E, Hehlmann R, Hochhaus A, Oscier D, Silver RT, Reiter A, Cross NC (2005) Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 106: 2162–2168PubMedCrossRefGoogle Scholar
  27. Campbell PJ, Green AR (2006) The myeloproliferative disorders. N Engl J Med 355: 2452–2466PubMedCrossRefGoogle Scholar
  28. Parandani AD, Levine RL, Lasho T, et al (2006) MPL 515 mutations in myeloproloferative and other myeloid disorders: a study of 1182 patients. Blood 108: 3472–3476CrossRefGoogle Scholar
  29. Tefferi A (2007) JAK2 mutations in polycythemia vera – molecular mechanisms and clinical applications. N Engl J Med 356: 444–445PubMedCrossRefGoogle Scholar
  30. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110: 1092–7109PubMedCrossRefGoogle Scholar
  31. Vardiman JW, Brunning RD, Harris NL (2001) WHO histological classification of chronic myeloproliferative diseases. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) WHO classification of tumors: tumors of the hematopoietic and lymphatic tissues. International Agency for Research on Cancer (IARC) Press, Lyon, France, 17–44Google Scholar
  32. Mesa AR (2007) Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. ASH Education Program Book 355–362Google Scholar
  33. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350: 114–124PubMedCrossRefGoogle Scholar
  34. Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353: 33–45PubMedCrossRefGoogle Scholar
  35. Dupriez B, Morel P, Demory JL, Lai JL, Simon M, Plantier I, Bauters F (1996) Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 88: 1013–1018PubMedGoogle Scholar
  36. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD (1995) Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. PNAS 92: 10560–10564PubMedCrossRefGoogle Scholar
  37. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, Marone G, Nuñez R, Akin C, Sotlar K, Sperr WR, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert K, Metcalfe DD, Vardiman JW, Bennett JM (2001) Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 25: 603–625PubMedCrossRefGoogle Scholar
  38. Gotlib J, Cools J, Malone JM, Schrier SL, Gilliland G, Coutré SE (2004) The FIP1L1-PDGFR-α fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukaemia: implications for diagnosis, classification and management. Blood 103: 2879–2891PubMedCrossRefGoogle Scholar
  39. Pardanani A, Reeder T, Porrata LF, Li CY, Tazelaar HD, Baxter EJ, Witzig TE, Cross NC, Tefferi A (2003) Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorder. Blood 101: 3391–3397PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Ernst Rechberger
    • 1
  • Gerald Webersinke
    • 2
  • Andreas L. Petzer
    • 1
    • 2
  1. 1.Interne I, Klinische Abteilung für Hämatologie und OnkologieKrankenhaus der Barmherzigen Schwestern LinzLinzAustria
  2. 2.Interne I, Labor für Molekularbiologie und TumorzytogenetikKrankenhaus der Barmherzigen Schwestern LinzLinzAustria

Personalised recommendations